Vancouver, BC and Boston, MA, June 27, 2018 – Imagin Medical (CSE: IME) (OTCPINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce that its common shares were approved for uplisting from the Pink Open Market to the OTCQB Venture Market (“OTCQB”), effective June 28, 2018.
“Uplisting to OTCQB is an important milestone in our evolution as a public company,” commented Jim Hutchens, Imagin’s President and CEO. “We believe this should help with our continuing efforts to broaden our exposure within the investment community, diversify our shareholder base and improve the trading liquidity of our shares.”
The OTCQB is a venture market designed for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process.
About Imagin Medical
Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving their ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Jim Hutchens, President & CEO
Email: [email protected]
Stephen Kilmer, Investor Relations
Email: [email protected]